Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Isavuconazole: Case Report and Pharmacokinetic Considerations.

Marchesi F, Girmenia C, Goffredo BM, Salvatorelli E, Romano A, Mengarelli A, Minotti G, Menna P.

Chemotherapy. 2018 Nov 20;63(5):253-256. doi: 10.1159/000494329. [Epub ahead of print]

PMID:
30458443
2.

The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines.

Menna P, Salvatorelli E, Armento G, Annibali O, Greco C, Marchesi F, Calabrese V, Reggiardo G, Minotti G.

J Pharmacol Exp Ther. 2018 Dec;367(3):518-527. doi: 10.1124/jpet.118.253104. Epub 2018 Oct 1.

PMID:
30275150
3.

Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy.

Menna P, Calabrese V, Armento G, Annibali O, Greco C, Salvatorelli E, Marchesi F, Reggiardo G, Minotti G.

J Pharmacol Exp Ther. 2018 Jul;366(1):158-168. doi: 10.1124/jpet.118.249235. Epub 2018 May 2.

PMID:
29720563
4.

Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy.

Menna P, Salvatorelli E, Mattei A, Cappiello D, Minotti G, Carassiti M.

Chemotherapy. 2018;63(1):35-38. doi: 10.1159/000484974. Epub 2017 Dec 22.

5.

Low-Dose Anthracycline and Risk of Heart Failure in a Pharmacokinetic Model of Human Myocardium Exposure: Analog Specificity and Role of Secondary Alcohol Metabolites.

Salvatorelli E, Menna P, Chello M, Covino E, Minotti G.

J Pharmacol Exp Ther. 2018 Feb;364(2):323-331. doi: 10.1124/jpet.117.246140. Epub 2017 Dec 8.

PMID:
29222131
6.

Cancer drugs and QT prolongation: weighing risk against benefit.

Menna P, Salvatorelli E, Minotti G.

Expert Opin Drug Saf. 2017 Oct;16(10):1099-1102. doi: 10.1080/14740338.2017.1354987. Epub 2017 Jul 20. No abstract available.

PMID:
28699784
7.

Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose Doxorubicin.

Salvatorelli E, Menna P, Chello M, Covino E, Minotti G.

J Pharmacol Exp Ther. 2017 Aug;362(2):263-270. doi: 10.1124/jpet.117.242388. Epub 2017 May 30.

8.

Do You Know Pixantrone?

Minotti G, Menna P, Salvatorelli E.

Chemotherapy. 2017;62(3):192-193. doi: 10.1159/000464276. Epub 2017 Mar 24. No abstract available.

9.

Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview.

Menna P, Salvatorelli E.

Chemotherapy. 2017;62(3):159-168. doi: 10.1159/000455823. Epub 2017 Jan 26.

10.

Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant.

Renzi D, Marchesi F, De Angelis G, Elia L, Salvatorelli E, Gumenyuk S, Palombi F, Pisani F, Romano A, Spadea A, Papa E, Canfora M, Arcese W, Mengarelli A; Rome Transplant Network.

Chemotherapy. 2017;62(1):58-61. Epub 2016 Sep 10.

11.

Rethinking Drugs from Chemistry to Therapeutic Opportunities: Pixantrone beyond Anthracyclines.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2016 Aug 15;29(8):1270-8. doi: 10.1021/acs.chemrestox.6b00190. Epub 2016 Jul 22.

PMID:
27420111
12.

Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.

Salvatorelli E, Menna P, Minotti G.

Future Cardiol. 2015 Jul;11(4):363-6. doi: 10.2217/FCA.15.35. Epub 2015 Aug 4. No abstract available.

PMID:
26239550
13.

The concomitant management of cancer therapy and cardiac therapy.

Salvatorelli E, Menna P, Cantalupo E, Chello M, Covino E, Wolf FI, Minotti G.

Biochim Biophys Acta. 2015 Oct;1848(10 Pt B):2727-37. doi: 10.1016/j.bbamem.2015.01.003. Epub 2015 Jan 14. Review.

14.

Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship.

Menna P, Gallo P, Vespasiani Gentilucci U, Salvatorelli E, Galati G, Minotti G, Picardi A.

J Viral Hepat. 2014 Oct;21(10):e136-7. doi: 10.1111/jvh.12264. Epub 2014 Jun 16. No abstract available.

PMID:
24935352
15.

Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox.

Cacciapaglia F, Salvatorelli E, Minotti G, Afeltra A, Menna P.

Cardiovasc Toxicol. 2014 Dec;14(4):387-92. doi: 10.1007/s12012-014-9257-z.

PMID:
24798036
16.

The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.

Salvatorelli E, Menna P, Paz OG, Chello M, Covino E, Singer JW, Minotti G.

J Pharmacol Exp Ther. 2013 Feb;344(2):467-78. doi: 10.1124/jpet.112.200568. Epub 2012 Nov 28.

17.

Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.

Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, Iacobelli S, Minotti G.

Drug Metab Dispos. 2012 Dec;40(12):2365-73. doi: 10.1124/dmd.112.047480. Epub 2012 Sep 12.

18.

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.

Salvatorelli E, Menna P, Gonzalez Paz O, Surapaneni S, Aukerman SL, Chello M, Covino E, Sung V, Minotti G.

J Pharmacol Exp Ther. 2012 May;341(2):474-83. doi: 10.1124/jpet.111.190264. Epub 2012 Feb 15.

19.

Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. I. Amrubicin accumulates to a lower level than doxorubicin or epirubicin.

Salvatorelli E, Menna P, Surapaneni S, Aukerman SL, Chello M, Covino E, Sung V, Minotti G.

J Pharmacol Exp Ther. 2012 May;341(2):464-73. doi: 10.1124/jpet.111.190256. Epub 2012 Feb 15.

20.

Anthracycline cardiotoxicity.

Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, Minotti G.

Expert Opin Drug Saf. 2012 May;11 Suppl 1:S21-36. doi: 10.1517/14740338.2011.589834. Epub 2011 Jun 2. Review.

PMID:
21635149
21.

Matters of the heart: the case of TNFalpha-targeting drugs.

Cacciapaglia F, Menna P, Navarini L, Afeltra A, Salvatorelli E, Minotti G.

Mol Interv. 2011 Apr;11(2):79-87. doi: 10.1124/mi.11.2.4. No abstract available.

PMID:
21540466
22.

Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues.

Cacciapaglia F, Navarini L, Menna P, Salvatorelli E, Minotti G, Afeltra A.

Autoimmun Rev. 2011 Aug;10(10):631-5. doi: 10.1016/j.autrev.2011.04.014. Epub 2011 Apr 22. Review.

PMID:
21539939
23.

Pharmacological foundations of cardio-oncology.

Minotti G, Salvatorelli E, Menna P.

J Pharmacol Exp Ther. 2010 Jul;334(1):2-8. doi: 10.1124/jpet.110.165860. Epub 2010 Mar 24.

24.

Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2010 Jan;23(1):6-10. doi: 10.1021/tx9003424.

PMID:
19954191
25.

4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2009 Jun;22(6):978-83. doi: 10.1021/tx900039p.

PMID:
19397277
26.

Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart.

Salvatorelli E, Menna P, Lusini M, Covino E, Minotti G.

J Pharmacol Exp Ther. 2009 Apr;329(1):175-84. doi: 10.1124/jpet.108.149260. Epub 2009 Jan 14.

27.

Cardiotoxicity of antitumor drugs.

Menna P, Salvatorelli E, Minotti G.

Chem Res Toxicol. 2008 May;21(5):978-89. doi: 10.1021/tx800002r. Epub 2008 Apr 1.

PMID:
18376852
28.

Anthracycline cardiotoxicity.

Menna P, Salvatorelli E, Gianni L, Minotti G.

Top Curr Chem. 2008;283:21-44. doi: 10.1007/128_2007_11.

PMID:
23605627
29.

Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.

Gianni L, Salvatorelli E, Minotti G.

Cardiovasc Toxicol. 2007;7(2):67-71. Review.

PMID:
17652806
30.

Doxorubicin degradation in cardiomyocytes.

Menna P, Salvatorelli E, Minotti G.

J Pharmacol Exp Ther. 2007 Jul;322(1):408-19. Epub 2007 Apr 27.

31.

Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.

Salvatorelli E, Menna P, Gianni L, Minotti G.

J Pharmacol Exp Ther. 2007 Feb;320(2):790-800. Epub 2006 Nov 29.

32.

In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.

Menna P, Minotti G, Salvatorelli E.

Cell Biol Toxicol. 2007 Jan;23(1):49-62. Epub 2006 Oct 9. Review.

PMID:
17031515
33.

Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies.

Salvatorelli E, Menna P, Cascegna S, Liberi G, Calafiore AM, Gianni L, Minotti G.

J Pharmacol Exp Ther. 2006 Jul;318(1):424-33. Epub 2006 Apr 13.

34.

Defective one- or two-electron reduction of the anticancer anthracycline epirubicin in human heart. Relative importance of vesicular sequestration and impaired efficiency of electron addition.

Salvatorelli E, Guarnieri S, Menna P, Liberi G, Calafiore AM, Mariggiò MA, Mordente A, Gianni L, Minotti G.

J Biol Chem. 2006 Apr 21;281(16):10990-1001. Epub 2006 Jan 19.

35.

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.

Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L.

Pharmacol Rev. 2004 Jun;56(2):185-229. Review.

36.

Doxorubicin cardiotoxicity and the control of iron metabolism: quinone-dependent and independent mechanisms.

Minotti G, Recalcati S, Menna P, Salvatorelli E, Corna G, Cairo G.

Methods Enzymol. 2004;378:340-61. Review. No abstract available.

PMID:
15038979
37.

Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.

Sessa C, Perotti A, Salvatorelli E, Minotti G, Viganò L, Lladò A, Capri G, Locatelli A, Colombini S, Peccatori F, Voi M, Marsoni S, Gianni L.

Eur J Cancer. 2004 Mar;40(4):563-70.

PMID:
14962724
38.

Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin.

Cartoni A, Menna P, Salvatorelli E, Braghiroli D, Giampietro R, Animati F, Urbani A, Del Boccio P, Minotti G.

J Biol Chem. 2004 Feb 13;279(7):5088-99. Epub 2003 Nov 21.

39.

Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.

Sacco G, Giampietro R, Salvatorelli E, Menna P, Bertani N, Graiani G, Animati F, Goso C, Maggi CA, Manzini S, Minotti G.

Br J Pharmacol. 2003 Jun;139(3):641-51.

40.

Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines.

Menna P, Salvatorelli E, Giampietro R, Liberi G, Teodori G, Calafiore AM, Minotti G.

Chem Res Toxicol. 2002 Sep;15(9):1179-89.

PMID:
12230412
42.

Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.

Minotti G, Parlani M, Salvatorelli E, Menna P, Cipollone A, Animati F, Maggi CA, Manzini S.

Br J Pharmacol. 2001 Nov;134(6):1271-8.

Supplemental Content

Loading ...
Support Center